logo-loader
viewShield Therapeutics PLC

Shield Therapeutics to continue “robust” defence of IP as Teva appeals Feraccru ruling

The pharmaceutical firm said no date for the appeal hearing had yet been set but it believed the initial EPO decision in its favour would be upheld

Appeal
Teva is appealing an initial EPO decision in favour of Shield in March

Shield Therapeutics PLC (LON:STX) has said it will continue to “robustly defend” its intellectual property (IP) after receiving notice that Teva Pharmaceutical Industries Ltd had appealed a ruling by the European Patent Office (EPO) regarding STX’s Feraccru iron deficiency treatment.

The news followed an EPO decision in March when it found in favour of Shield in relation to patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone".

WATCH: Shield Therapeutics accelerating commercial plans ahead of FDA decision

Shield said no date for the appeal hearing had yet been set but it believed the initial EPO decision would be upheld and would update on proceedings as required.

In a note, analysts at Shield’s ‘house’ broker Peel Hunt said appeals of this kind were “typical” of the generics industry and the original decision and breadth of the Feraccru patent provided significant defensibility for the company’s IP.

In early trading on Monday, Shield shares were 7% lower at 106p.

--Adds share price--

Quick facts: Shield Therapeutics PLC

Price: 184 GBX

LSE:STX
Market: LSE
Market Cap: £215.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: Analyst discusses further positive data from...

Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study. It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose...

2 weeks, 5 days ago

2 min read